Stop of treatment in COVID-19 study

Boehringer Ingelheim stops treatment with experimental medication in study investigating benefits for severely ill patients with COVID-19Phase II study assessing BI 764198, a novel first-in-class compound, for patients hospitalized with COVID-19 with respiratory complications discontinued due to lack of efficacy in this indicationBoehringer Ingelheim remains committed to other research and development efforts in COVID-19 including new SARS-CoV-2 neutralizing antibodies
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news